This indicates that TGF-β signaling in the more aggressive type II endometrial carcinoma has tumor promoting effects, whereas it has been shown that in the estrogen-dependent type I endometrial carcinoma, the TGF-β signaling pathway is disrupted [17-19] and thus has a tumor inhibiting role. Here, TGFB1 is linked to endometrial carcinoma.